Mr. David Regan reports

SONA NANOTECH ANNOUNCES DIRECTOR RETIREMENT

Dr. Michael Gross has retired from Sona Nanotech Inc.'s board of directors to focus on other business interests.

"Mike has been a valuable member of Sona's board, and we wish him great success in his future endeavours," stated Mark Lievonen, chair of Sona.

Dr. Gross commented: "I am proud of the recent accomplishments the company has made during my tenure. I believe that the company will realize significant opportunities as it continues to advance its work using gold nanorod technologies in the treatment of cancer."

About Sona Nanotech Inc.

Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumour and re-emitted as heat. Therapeutic heat (41 to 48 degrees) stimulates the immune system, shrinks tumours, inactivates cancer stem cells and increases tumour perfusion -- thus enabling drugs to reach all tumour compartments more effectively. The size, shape and surface chemistry of the nanorods target the leaky vasculature of solid tumours, and the selective thermal sensitivity of tumour tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona's initial clinical target is colorectal cancer.

We seek Safe Harbor.